Induction of Myogenic Differentiation Improves Chemosensitivity of Chemoresistant Cells in Soft-Tissue Sarcoma Cell Lines

Lucy E Dawson; Luca D'Agostino; Abraham A Hakim; Richard D Lackman; Spencer A Brown; Richard B Sensenig; Zeus A Antonello; Igor I Kuzin

doi:10.1155/2020/8647981

Induction of Myogenic Differentiation Improves Chemosensitivity of Chemoresistant Cells in Soft-Tissue Sarcoma Cell Lines

Sarcoma. 2020 Mar 26:2020:8647981. doi: 10.1155/2020/8647981. eCollection 2020.

Authors

Lucy E Dawson¹, Luca D'Agostino¹, Abraham A Hakim², Richard D Lackman^{1

3}, Spencer A Brown¹, Richard B Sensenig¹, Zeus A Antonello^{1

2}, Igor I Kuzin^{1

2}

Affiliations

¹ Cooper University Hospital, Camden, NJ, USA.
² Cooper Medical School of Rowan University, Camden, NJ, USA.
³ MD Anderson Cancer Center at Cooper, Camden, NJ, USA.

Abstract

Rhabdomyosarcoma (RMS) and rhabdoid tumors (RT) are rare soft-tissue malignancies with the highest incidence in infants, children, and adolescents. Advanced, recurrent, and/or metastatic RMS and RT exhibit poor response to treatment. One of the main mechanisms behind resistance to treatment is believed to be intratumoral heterogeneity. In this study, we investigated the myogenic determination factor 1 (MYOD1) and Noggin (NOG) markers in an embryonal RMS (ERMS) cell line and an RT cell line and the differential response of the MYOD1 and NOG expressing subpopulations to chemotherapy. Importantly, we found that these markers together identify a subpopulation of cells (MYOD1+ NOG+ cells) with primary resistance to Vincristine and Doxorubicin, two commonly used chemotherapies for ERMS and RT. The chemoresistant MYOD1+ NOG+ cells express markers of undifferentiated cells such as myogenin and ID1. Combination of Vincristine with TPA/GSK126, a drug combination shown to induce differentiation of RMS cell lines, is able to partially overcome MYOD1/NOG cells chemoresistance.